---
document_datetime: 2024-12-12 17:01:32
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/relistor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: relistor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.3917671
conversion_datetime: 2025-12-21 19:11:08.460328
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Relistor

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0065/G            | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 11/12/2024                          |                                             | SmPC, Labelling and PL           |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | B.IV.1.z - Change of a measuring or administration device - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                 |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| IAIN/0066   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                               | 06/09/2024 | n/a |                 |
| IAIN/0064   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/06/2024 | n/a |                 |
| IAIN/0063   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/02/2024 | n/a |                 |
| IAIN/0062/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 04/12/2023 |     | Annex II and PL |
| IAIN/0061/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                                                                                                                                                                 | 21/12/2022 | n/a |                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | site A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| IB/0060/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.i - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Where there is no monograph in the European/National Ph. for the AS, a change in specification from in-house to a non- official/third country Ph. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.z - Quality change - Active substance - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder the AS, starting material, reagent or | 19/12/2022 | n/a | or supplier of |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------|
| IB/0059/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.c.1.z - Change in immediate packaging of the AS - Other variation B.I.z - Quality change - Active substance - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method Administrative change - Change in the name | 08/12/2022 | n/a | A.4 - |

<div style=\"page-break-after: always\"></div>

|                    | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                               |            |            |                        |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/2023/ 202203 | Periodic Safety Update EU Single assessment - methylnaltrexone bromide                                                                                                                                                                 | 01/12/2022 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0058          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 28/10/2022 | 04/10/2023 | Annex II and PL        |                                   |
| IA/0056            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                       | 07/07/2021 | n/a        |                        |                                   |
| IB/0054            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                         | 19/01/2021 | n/a        |                        |                                   |
| IAIN/0055          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 11/12/2020 | 09/12/2021 | Annex II and PL        |                                   |
| T/0053             | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 15/11/2019 | 16/12/2019 | SmPC, Labelling and PL |                                   |
| PSUSA/2023/        | Periodic Safety Update EU Single assessment -                                                                                                                                                                                          | 31/10/2019 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| 201903    | methylnaltrexone bromide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|
| IAIN/0051 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 29/04/2019 | n/a        |                  |
| IB/0050   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/01/2019 | n/a        |                  |
| N/0048    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/12/2018 | 16/12/2019 | Labelling and PL |
| IB/0047/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits | 21/03/2018 | n/a        |                  |

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                           |            |            |                 |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0046/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                          | 06/02/2018 | n/a        |                 |                                                                                                                                           |
| IB/0045            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                       | 18/09/2017 | n/a        |                 |                                                                                                                                           |
| PSUSA/2023/ 201603 | Periodic Safety Update EU Single assessment - methylnaltrexone bromide                                                                                                                                                                                                                                                                               | 10/11/2016 | 09/01/2017 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2023/201603. |
| IAIN/0044/G        | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of | 13/07/2016 | 09/01/2017 | Annex II and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| A.7 - Administrative change manufacturing sites A.7 - Administrative change manufacturing sites B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.c.1 - Change arrangements and quality Replacement or addition responsible for importation Not including batch control/testing B.II.b.2.c.1 - Change arrangements and quality Replacement or addition responsible for importation Not including batch control/testing B.II.b.2.c.1 - Change arrangements and quality Replacement or addition responsible for importation Not including batch control/testing   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                    | arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                  |            |            |                        |                                                                                                        |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------|
| N/0042             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                       | 30/05/2016 | 09/01/2017 | PL                     |                                                                                                        |
| T/0041             | Transfer of Marketing Authorisation from TMC Pharma Services Ltd. to PharmaSwiss Ceska Republika s.r.o Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                             | 21/12/2015 | 28/01/2016 | SmPC, Labelling and PL | Transfer of Marketing Authorisation from TMC Pharma Services Ltd. to PharmaSwiss Ceska Republika s.r.o |
| II/0039            | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                                                                                                                                                     | 26/11/2015 | n/a        |                        |                                                                                                        |
| PSUSA/2023/ 201503 | Periodic Safety Update EU Single assessment - methylnaltrexone bromide                                                                                                                                                                                                                                                                                                                                                                 | 08/10/2015 | n/a        |                        | PRAC Recommendation - maintenance                                                                      |
| IB/0040/G          | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products | 21/09/2015 | n/a        |                        |                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products   |            |            |             |                                                                                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------|
| IA/0037/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                | 08/06/2015 | n/a        |             |                                                                                                   |
| II/0030   | Extension of Indication to include the treatment of opioid-induced constipation in non-cancer adult patients when response to laxative therapy has not been sufficient; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) -                                                                                                                                                         | 23/04/2015 | 27/05/2015 | SmPC and PL | Please refer to the scientific discussion Relistor EMEA/H/C/000870/II/30 for further information. |

<div style=\"page-break-after: always\"></div>

|             | Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                 |                                   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUV/0032   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 09/10/2014 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0035     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/08/2014 | 11/09/2014 | SmPC            |                                   |
| IAIN/0034   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 25/07/2014 | n/a        |                 |                                   |
| IA/0033     | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                             | 10/07/2014 | n/a        |                 |                                   |
| IAIN/0031/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release | 23/06/2014 | 11/09/2014 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing           |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029   | The MAH submitted for assessment the CSR of a randomised controlled trial after preliminary closure and as requested by PRAC during the assessment of PSUR 8. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                  | 20/03/2014 | n/a        |                       | The purpose of the study was to assess the safety and efficacy of methylnaltrexone in the Asian patient population and to evaluate the pharmacokinetics profile in Asian subjects. The study was closed due to the infeasibility to recruit a sufficient number of patients. There were no safety concerns leading to termination. Overall, efficacy and safety results revealed nothing substantially new. No change to the Product Information was considered necessary based on these results. |
| II/0028   | Update of section 4.8 of the SmPC in order to add vomiting as an undesirable effect. The Package Leaflet is updated accordingly. Furthermore, the PI is being brought in line with the latest QRD template version 9. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 19/09/2013 | 11/09/2014 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IAIN/0027 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                               | 15/07/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IB/0026   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                    | 26/06/2013   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0022    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 21/03/2013   | 27/05/2013 | SmPC, Annex II, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of Relistor continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Relistor continues to be favourable in the Treatment of opioid-induced constipation in advance illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient. |
| N/0024    | To include an additional warning on the tray label of the vial presentation to state that the syringe needle retracts after use. The MAH also took the opportunity to add the contact email address for TMC Pharma Services Ltd. in the package leaflet for Estonia, Finland, France, Malta and Slovakia in order to make consistent with the annexes for the rest of the Member States. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 21/01/2013   | 27/05/2013 | Labelling                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IAIN/0023 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                         | 14/12/2012   | 27/05/2013 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IA/0021   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                           | 31/08/2012   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0018   | Update of section 5.3 of the SmPC to reflect the results of carcinogenicity studies RPT-74168 in mice and RPT-74169 in rats. Furthermore the MAH took the opportunity to adapt the PI to the current QRD template, and to delete the DDPS version number from Annex II. B. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 23/06/2011   | 27/07/2011 | SmPC, Annex II and PL  | Two 104-week oral gavage carcinogenicity studies in cesarean-derived (CD)-1 mice and Sprague-Dawley (S-D) rats were performed. In these studies, male and female rats were administered oral doses up to 300 mg/kg/day (approximately 4 times the exposures (AUC) in humans at the subcutaneous dose of 0.15 mg/kg) and mice were administered oral dosages up to 200 mg/kg/day for males or 400 mg/kg/day for females (approximately 13 times and 21 times, respectively, the exposure (AUC) in humans at the subcutaneous dose of 0.15 mg/kg). Both studies did not show carcinogenic potential for methylnaltrexone. |
| T/0019    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                               | 14/06/2011   | 05/07/2011 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| WS/0117   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.8.b - Introduction of a new Pharmacovigilance system - which has been assessed by the relevant NCA/EMA for another product of the same MAH                                                                                                                                      | 14/04/2011   | 17/06/2011 | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0017   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                     | 04/11/2010   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| X/0006   | Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24/06/2010   | 06/09/2010   | SmPC, Labelling and PL   | Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the risk- benefit balance of Relistor pre-filled syringes 8 mg/ 0.4 ml and 20 mg/ 0.6 ml in the treatment of opioid induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient was favourable and therefore recommended the granting of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016  | Update of section 4.4 and 4.8 of the SmPC to add information relating to intestinal perforation following a cumulative review of medically confirmed cases of gastrointertinal perforation. The Package leaflet is updated accordingly. The MAH also took the opportunity to a correct section 4.8 to reorder the listed 'Very Common' adverse reactions under Gastrointestinal Disorders in order of importance. This variation application is submitted further to the request of the CHMP following assessment of PSUR Nr. 3, covering the period 28.03.09 - 27.09.09. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 22/07/2010   | 01/09/2010   | SmPC and PL              | A review of spontaneous postmarketing reporting until 31 March 2010 identified 10 cases of gastrointestinal perforation medically confirmed. Although patients who experienced gastrointestinal perforation had conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the gastrointestinal tract such as cancer, peptic ulcer or pseudo-obstruction, Relistor may have contributed to these events. Therefore in order to increase awareness of prescribers and patients and in order to facilitate early diagnosis and treatment of such event a warning is added in the product information. Healthcare professional are recommended to use methylnaltrexone bromide with caution in patients with known or suspected lesions of the gastrointestinal tract. It is also advised to patients to promptly report severe, persistent, and/or worsening of gastrointestinal symptoms. The event gastrointestinal perforation is also added to section 4.8 of the SmPC as new undesirable effect observed in postmarketing setting. |
| II/0008  | Update of section 5.3 of the SmPC as a result of the completion of non-clinical tolerability and toxicity studies in juvenile rats and dogs. In addition the MAH took the opportunity to make some language                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/05/2010   | 05/07/2010   | SmPC and PL              | Studies have been conducted in juvenile rats and dogs. Following intravenous injection of methylnaltrexone bromide, juvenile rats were found to be more sensitive than adult rats to methylnaltrexone-related toxicity. In                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | corrections to the German and Slovakian versions of the SmPC. The full list of local representatives is also updated in the Package Leaflet. Paediatrics to validate Update of Summary of Product Characteristics and Package Leaflet   |            |     |                        | juvenile rats administered intravenous methylnaltrexone bromide for 13 weeks, adverse clinical signs (incidences of convulsions and laboured breathing) occurred at dosages (? 3 mg/kg/day) and exposures (5.4 times the exposure [AUC] in adult humans at a subcutaneous dose of 0.15 mg/kg) that were lower than those that caused similar toxicity in adult rats (20 mg/kg/day). No adverse effects occurred in juvenile rats at 1 mg/kg/day or in adult rats at 5 mg/kg/day (1.6 times and 7.8 times, respectively, the exposure [AUC] in adult humans at a subcutaneous dose of 0.15 mg/kg). Following intravenous injection of methylnaltrexone bromide for 13 weeks, similar methylnaltrexone related toxicity was observed in both juvenile and adult dogs. In adult and juvenile dogs given methylnaltrexone bromide at 20 mg/kg/day, clinical signs indicative of CNS toxicity and prolongation of QTc interval were observed. No adverse effects occurred in either juvenile or adult dogs at a dose of 5 mg/kg/day (44 times the exposure {AUC} in adult humans at a subcutaneous   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0015 | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                | 05/05/2010 | n/a | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0014 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                               | 05/05/2010 | n/a | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0013 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of                                                                               | 22/04/2010 | n/a | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0012 | C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                          | 22/04/2010 | n/a        | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0011 | C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD                                                                                                                                                                                                                                                                                                | 22/04/2010 | n/a        | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0010 | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/04/2010 | n/a        | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0009 | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 22/04/2010 | n/a        | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0007 | Update of section 4.8 \"Undesirable effects\" of the Summary of Product Characteristics to add \"hyperhidrosis\" based on results of study 3200K1- 3356-WW. The PL was amended accordingly. The MAH took the opportunity to update the Package Leaflet with the text from the Patient Instructions and Patient Checklist Card as agreed by the CHMP in Follow-up measure RM2 026.1 on 29 May 2009. The MAH also amended the contact details of the local representative in Austria, Germany, Greece, Malta Portugal and Spain. Typographical errors were also | 19/11/2009 | 21/12/2009 | SmPC, Labelling and PL | Results from study 3200K1-3356-WW showed that the event \"hyperhidrosis\" was reported with a higher rate among the subjects receiving methylnaltrexone bromide than among subjects receiving placebo. Based on the incidence reported in the trial (6.0% to 6.1%) the event is reported in the SmPC with a frequency category of common under the Skin and Subcutaneous tissue disorders system organ class. The PL has been updated accordingly. The Patient Instructions have been updated and a Patient Checklist added in line with the CHMP conclusion on RM2 |

<div style=\"page-break-after: always\"></div>

|         | corrected throughout the SmPC. Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                                                                                                                                                                                                                                   |            |            |                       | 026.1.                                                                                                                                                                                                                                                                                                                                                       |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003 | Update of the DDPS (Module 1.8.1) to reflect a change in the Qualified Person in the EEA for Pharmacovigilance (QPPV). Other administrative and editorial changed are incorporated in this revised DDPS (version 2.1). Annex II of the Product Information has been updated using standard text including the new version number for the DDPS (version 2.1). Changes to QPPV | 29/05/2009 | 03/07/2009 | SmPC, Annex II and PL | Update of the DDPS (Module 1.8.1) to reflect a change in the Qualified Person in the EEA for Pharmacovigilance (QPPV). Other administrative and editorial changed are incorporated in this revised DDPS (version 2.1). Annex II of the Product Information has been updated using standard text including the new version number for the DDPS (version 3.0). |
| IA/0005 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                            | 19/05/2009 | n/a        | Annex II and PL       |                                                                                                                                                                                                                                                                                                                                                              |
| II/0002 | The Marketing Authorisation Holder proposes a limit of not more than 125 ppm for the sum of two degradants. Quality changes                                                                                                                                                                                                                                                  | 23/04/2009 | 07/05/2009 |                       |                                                                                                                                                                                                                                                                                                                                                              |
| IB/0004 | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                                                                                | 07/05/2009 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                              |
| N/0001  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                             | 05/02/2009 | n/a        | PL                    |                                                                                                                                                                                                                                                                                                                                                              |